Home >> Doxorubicin
Related Products
Topo II inhibitor,immunosuppresive antineoplastic antibiotic

Catalog No.A3966
Size Price Stock Qty
10mM (in 1mL DMSO)
In stock
Evaluation Sample
In stock
In stock
In stock
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors


Sample solution is provided at 25 µL, 10mM.

Product Citations

1. Deng Y, Li F, et al. "Triptolide sensitizes breast cancer cells to Doxorubicin through the DNA damage response inhibition." Mol Carcinog. 2018 Jun;57(6):807-814. PMID:29500880

Quality Control

Chemical structure


Related Biological Data

Cells were incubated with YSK-MEND for 24h, and then trypsinized and reseeded in 24-well plates. 24 h after reseeding, the cells were washed with PBS and incubated with DOX-containing medium for 6h. DOX-containing medium was removed, and cells were washed with PBS and recovered 18 h after fresh medium incubation. Protein concentrations determined by the CA method were regarded as a viability. Values indicate mRNA expression relative to nontreatment (NT) ± SD.

Related Biological Data


Biological Activity

Description Doxorubicin (Adriamycin) is an antibiotic agent, inhibitor of DNA topoisomerase II and inducer of DNA damage and apoptosis.
Targets Autophagy          


Cell experiment [1]:

Cell lines

MDA-MB-231 cells

Preparation method

This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 ℃ for several months.

Reaction Conditions

20 nM; 72 hrs


In MDA-MB-231 cells, SH003 at 120 μg/mL with Doxorubicin at 20 nM showed a synergistic effect.

Animal experiment [2]:

Animal models

Female athymic nude mice injected s.c. with MB231 cells

Dosage form

3 mg/kg/day; delivered intratumorly


Doxorubicin in combination with adenoviral MnSOD (AdMnSOD) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) showed the greatest effect in decreasing the volumes of MB231 tumors and prolonging survival of mice.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


[1]. Woo SM, Kim AJ, Choi YK, Shin YC, Cho SG, Ko SG. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer. Phytother Res. 2016 Aug 1.

[2]. Sun W, Kalen AL, Smith BJ, Cullen JJ, Oberley LW. Enhancing the antitumor activity of adriamycin and ionizing radiation. Cancer Res. 2009 May 15;69(10):4294-300.

Doxorubicin Dilution Calculator

Concentration (start)
Volume (start)
Concentration (final)
Volume (final)


Doxorubicin Molarity Calculator



Chemical Properties

Cas No. 23214-92-8 SDF Download SDF
Synonyms Adriamycin, Doxil, Adriablastin, Doxorubicinum, Myocet
Chemical Name (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
Canonical SMILES CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O
Formula C27H29NO11 M.Wt 543.52
Solubility >27.2mg/mL in DMSO Storage Store at RT
Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Research Update

4. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol. 2013 Oct;43(10):2718-29. doi: 10.1002/eji.201242505. Epub 2013 Jul 11.
Doxorubicin enhanced tumor infiltration by IFN-γ-secreting Tcells and decreased the content of TAMs in MMTV-neu mice.
5. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients. Gynecol Oncol. 2013 Dec;131(3):683-8. doi: 10.1016/j.ygyno.2013.09.031. Epub 2013 Oct 4.
Although a few factors, including body composition, age, gender, changes in monocyte count and repeated dosing, have impacts on pharmacokinetic properties of PLD, clinical risk factors of ovarian cancer patients who have PPE and receive PLD are rarely identified.


Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin intercalates into DNA double strand and inhibits the progression of DNA topoisomerase II, stopping replication process. [2] Doxorubicin also induces histone eviction from open chromatin, causing DNA damage and epigenetic deregulation. [3]

Doxorubicin is administrated intravenously. Approximately 75% of doxorubicin and its metabolites bind to plasma protein. Doxorubicin does not cross blood brain barrier. 50% of the drug is eliminated unchanged from the body mainly though bile excretion. The remaining undergoes one-electron reduction, two-electron reduction, and deglycosidation. The major metabolite is a potent membrane ion pump inhibitor, which is associated with cardiomyopathy. [4]

[1]Brayfield, A, ed. (2013). Doxorubicin. Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 15 April 2014.
[2]Pommier Y., et al. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & Biology 17 (5): 421–433.
[3]Pang, B., et al. (2013). Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications 4 (5): 1908
[4]Boucek RJ., et al. (1987). The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J of Biol Chem 262: 15851-15856.